JNJ Stock Recent News

Johnson & Johnson's JNJ stock price advance has been reinvigorated. The stock price rally stalled a few years ago due to the COVID-19 bubble bursting and the divestiture of Kenvue KVUE, but those days are behind, and business growth is still ahead.

Johnson & Johnson infused positive optimism after posting solid third-quarter 2024 earnings. A few analysts raised their target price on the stock.

Johnson & Johnson (NYSE: JNJ) recently reported its Q3 results, with revenues and earnings exceeding our estimates. The company reported revenue of $22.5 billion and adjusted earnings of $2.42 per share, compared to our estimates of $22.2 billion and $2.20, respectively.

Johnson & Johnson's latest financial checkup shows it's still in excellent health.

Johnson & Johnson's NYSE: JNJ stock price advance has been reinvigorated. The stock price rally stalled a few years ago due to the COVID-19 bubble bursting and the divestiture of Kenvue NYSE: KVUE, but those days are behind, and business growth is still ahead.

BRIDGEPORT, Conn.--(BUSINESS WIRE)--A Bridgeport jury has awarded Evan Plotkin and his wife Martha Barry-Plotkin $15 million in a verdict against pharmaceutical giant Johnson & Johnson (NYSE:JNJ) and several subsidiaries for damage linked to asbestos in the company's talc-based Baby Powder. “This trial demonstrated once again that J&J knew its products would cause harm, but they chose to do the wrong thing time and time again,” said Mr. Plotkin's attorney, Ben Braly of Dean Omar Branham.

Jay Hatfield, Infra-Cap CEO, joins 'Power Lunch' to discuss stock plays for three stocks.

Johnson & Johnson (JNJ) stock is experiencing a positive trading day following the announcement of its Q3 results for 2024. The earnings per share (EPS) surpassed estimates, although improved business performance was overshadowed by the recent acquisition of V-Wave, a cardiac device company.

U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling around 150 points on Tuesday.

Johnson & Johnson (NYSE:JNJ ) Q3 2024 Earnings Conference Call October 15, 2024 8:30 AM ET Company Participants Jessica Moore - Vice President, Investor Relations Joaquin Duato - Chairman & Chief Executive Officer Joe Wolk - Executive Vice President, Chief Financial Officer Erik Haas - Head, Worldwide Litigation Tim Schmid - Executive Vice President, Worldwide Chairman, MedTech Jennifer Taubert - Executive Vice President, Worldwide Chairman, Innovative Medicine John Reed - Executive Vice President, Innovative Medicine, R&D Conference Call Participants Chris Schott - JPMorgan Larry Biegelsen - Wells Fargo Louise Chen - Cantor Fitzgerald Terence Flynn - Morgan Stanley Danielle Antalffy - UBS Shagun Singh - RBC Capital Markets Vamil Divan - Guggenheim Securities Jayson Bedford - Raymond James Operator Good morning, and welcome to Johnson & Johnson's Third Quarter 2024 Earnings Conference Call. All participants will be in a listen-only mode until the question-and-answer session of the conf